<DOC>
	<DOCNO>NCT00848718</DOCNO>
	<brief_summary>The purpose study compare safety tolerability several dose level MK-2206 combination chemotherapy target therapy agent participant locally advance metastatic solid tumor .</brief_summary>
	<brief_title>A Phase I Study MK2206 Combination With Standard Chemotherapy Participants With Locally Advanced Metastatic Solid Tumors ( 2206-003 AM5 )</brief_title>
	<detailed_description />
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Inclusion Criteria : Participants must locally advance metastatic solid tumor . Participant male female great equal 18 year age . Participant must performance status less equal 1 Eastern Cooperative Oncology Group ( ECOG ) Performance Scale Female participant childbearing potential negative serum urine pregnancy test within 72 hour prior receive first dose study medication . Participants MK2206 + carboplatin/paclitaxel MK2206 + docetaxel treatment arm limit 3 prior cytotoxic therapy metastatic recurrent disease . Participant able swallow capsule surgical anatomical condition prevent Participant swallowing . Participant chemotherapy , radiotherapy biological therapy within 4 week . Participants must least 4 week postsurgery expect major surgery study duration . Participant currently participate participate study investigational compound device within 30 day . Participant know active central nervous system ( CNS ) metastases and/or carcinomatous meningitis . Participant primary central nervous system tumor . Participant known hypersensitivity component study drug . Participant history current evidence heart disease . Participant evidence clinically significant bradycardia ( slow heart rate ) . Participant uncontrolled high blood pressure . Participant significant risk hypokalemia ( low potassium level ) . Participant know diabetic Participant know psychiatric substance abuse disorder . Participant user illicit drug . Participant pregnant breastfeeding . Participant Human Immunodeficiency Virus ( HIV ) positive . Participant known history Hepatitis B C active Hepatitis A . Participant symptomatic ascites pleural effusion . Participant receive treatment oral corticosteroid . Participant use potent cytochrome P ( 450 ) 3A4 ( CYP3A4 ) inhibitor inducer .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Tumors , cancer</keyword>
</DOC>